| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment
|
Das, Brati
|
|
2019
|
|
3 |
p. 251-263
|
artikel
|
| 2 |
Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety
|
Lattanzi, Simona
|
|
|
|
3 |
p. 229-241
|
artikel
|
| 3 |
Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis
|
Lattanzi, Simona
|
|
2018
|
|
3 |
p. 189-196
|
artikel
|
| 4 |
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Wigal, Tim L.
|
|
2018
|
|
3 |
p. 289-301
|
artikel
|
| 5 |
Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis
|
Moujalled, Diane
|
|
2016
|
|
3 |
p. 227-243
|
artikel
|
| 6 |
Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data
|
Frol, Senta
|
|
|
|
3 |
p. 163-168
|
artikel
|
| 7 |
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
|
Sellebjerg, Finn
|
|
|
|
3 |
p. 269-280
|
artikel
|
| 8 |
Antineuronal Antibodies Against Neurotransmitter Receptors and Synaptic Proteins in Schizophrenia: Current Knowledge and Clinical Implications
|
Steiner, Johann
|
|
2015
|
|
3 |
p. 197-206
|
artikel
|
| 9 |
Antipsychotic Interventions in Prodromal Psychosis
|
Liu, Chen-Chung
|
|
2013
|
|
3 |
p. 197-205
|
artikel
|
| 10 |
Aphasia
|
Wallesch, Claus-W.
|
|
|
|
3 |
p. 203-213
|
artikel
|
| 11 |
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
|
Strzelczyk, Adam
|
|
|
|
3 |
p. 217-237
|
artikel
|
| 12 |
A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy
|
Gharaylou, Zeinab
|
|
2019
|
|
3 |
p. 283-291
|
artikel
|
| 13 |
A Revisited Strategy for Antiepileptic Drug Development in Children
|
Chiron, Catherine
|
|
2013
|
|
3 |
p. 185-195
|
artikel
|
| 14 |
Asenapine
|
Chwieduk, Claudine M.
|
|
|
|
3 |
p. 251-267
|
artikel
|
| 15 |
Author Correction to: l-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain
|
Cruccu, Giorgio
|
|
2018
|
|
3 |
p. 303
|
artikel
|
| 16 |
Authors’ Reply to Tsivgoulis et al.: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
|
Papadopoulos, Dimitrios
|
|
2019
|
|
3 |
p. 297-298
|
artikel
|
| 17 |
Benzodiazepine Use and Risk of Developing Alzheimer’s Disease: A Case-Control Study Based on Swiss Claims Data
|
Biétry, Fabienne A.
|
|
2017
|
|
3 |
p. 245-251
|
artikel
|
| 18 |
Binge Drinking: Current Diagnostic and Therapeutic Issues
|
Rolland, Benjamin
|
|
2017
|
|
3 |
p. 181-186
|
artikel
|
| 19 |
Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer’s Disease
|
Caffino, Lucia
|
|
|
|
3 |
p. 281-297
|
artikel
|
| 20 |
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
|
Doherty, Teodora
|
|
|
|
3 |
p. 299-310
|
artikel
|
| 21 |
Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine
|
Hennissen, Leonie
|
|
2017
|
|
3 |
p. 199-215
|
artikel
|
| 22 |
Catatonia in Patients with Autism: Prevalence and Management
|
Mazzone, Luigi
|
|
2014
|
|
3 |
p. 205-215
|
artikel
|
| 23 |
Cladribine Tablets
|
Muir, Victoria J.
|
|
|
|
3 |
p. 239-249
|
artikel
|
| 24 |
Clonidine Extended-Release In Attention-Deficit Hyperactivity Disordery
|
Croxtall, Jamie D.
|
|
2012
|
|
3 |
p. 277-279
|
artikel
|
| 25 |
Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard?
|
Taylor, David M.
|
|
2017
|
|
3 |
p. 177-180
|
artikel
|
| 26 |
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
|
Chakrabarty, Trisha
|
|
|
|
3 |
p. 291-304
|
artikel
|
| 27 |
Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
|
Tsivgoulis, Georgios
|
|
2019
|
|
3 |
p. 293-295
|
artikel
|
| 28 |
Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
|
Tsivgoulis, Georgios
|
|
|
|
3 |
p. 293-295
|
artikel
|
| 29 |
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis
|
Qiao, Yue
|
|
|
|
3 |
p. 169-192
|
artikel
|
| 30 |
COMT Inhibitors in the Management of Parkinson’s Disease
|
Fabbri, Margherita
|
|
|
|
3 |
p. 261-282
|
artikel
|
| 31 |
Convergent Mechanisms Underlying Rapid Antidepressant Action
|
Zanos, Panos
|
|
2018
|
|
3 |
p. 197-227
|
artikel
|
| 32 |
Correction to: Daridorexant in Insomnia Disorder: A Profile of Its Use
|
Nie, Tina
|
|
|
|
3 |
p. 291
|
artikel
|
| 33 |
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
|
Perumal, Jai
|
|
|
|
3 |
p. 275-289
|
artikel
|
| 34 |
Correction to: Quantitative Pharmaco-Electroencephalography in Antiepileptic Drug Research
|
Höller, Yvonne
|
|
2019
|
|
3 |
p. 299
|
artikel
|
| 35 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
|
Reder, Anthony T.
|
|
|
|
3 |
p. 317-330
|
artikel
|
| 36 |
Cranioselectivity of Sumatriptan Revisited: Pronounced Contractions to Sumatriptan in Small Human Isolated Coronary Artery
|
Chan, Kayi Y.
|
|
2014
|
|
3 |
p. 273-278
|
artikel
|
| 37 |
Cutaneous Adverse Effects of Neurologic Medications
|
Bahrani, Eman
|
|
|
|
3 |
p. 245-267
|
artikel
|
| 38 |
Cutaneous Adverse Effects of Neurologic Medications
|
Bahrani, Eman
|
|
2016
|
|
3 |
p. 245-267
|
artikel
|
| 39 |
Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression
|
Tsai, Shih-Jen
|
|
|
|
3 |
p. 243-253
|
artikel
|
| 40 |
Daridorexant in Insomnia Disorder: A Profile of Its Use
|
Nie, Tina
|
|
|
|
3 |
p. 267-274
|
artikel
|
| 41 |
Does Ketamine Have Anti-Suicidal Properties? Current Status and Future Directions
|
Price, Rebecca B.
|
|
2015
|
|
3 |
p. 181-188
|
artikel
|
| 42 |
Drug Treatment of Stroke in Patients with Antiphospholipid Antibodies
|
Dafer, Rima
|
|
|
|
3 |
p. 219-226
|
artikel
|
| 43 |
Early Experiences with Intrathecal Administration of Amphotericin B Liposomal Formulation at a Neurosurgical Center
|
Nailor, Michael D.
|
|
|
|
3 |
p. 225-229
|
artikel
|
| 44 |
Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study
|
Perlman, Amichai
|
|
|
|
3 |
p. 305-316
|
artikel
|
| 45 |
Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study
|
Luo, Zhen
|
|
|
|
3 |
p. 301-313
|
artikel
|
| 46 |
Efficacy and Safety of Ketamine in Patients with Complex Regional Pain Syndrome
|
Azari, Pari
|
|
2012
|
|
3 |
p. 215-228
|
artikel
|
| 47 |
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
|
Faissner, Simon
|
|
|
|
3 |
p. 269-287
|
artikel
|
| 48 |
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
|
Faissner, Simon
|
|
2018
|
|
3 |
p. 269-287
|
artikel
|
| 49 |
Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
|
Elshafay, Abdelrahman
|
|
2019
|
|
3 |
p. 239-250
|
artikel
|
| 50 |
Epidemiology and Management of Neuropsychiatric Disorders in Behçet’s Syndrome
|
Talarico, Rosaria
|
|
2015
|
|
3 |
p. 189-196
|
artikel
|
| 51 |
Excessive Daytime Sleepiness in Patients with Parkinson’s Disease
|
Knie, Bettina
|
|
|
|
3 |
p. 203-212
|
artikel
|
| 52 |
Feasibility of Following up Gamma-Hydroxybutyric Acid Concentrations in Sodium Oxybate (Xyrem®)-Treated Narcoleptic Patients Using Dried Blood Spot Sampling at Home
|
Ingels, Ann-Sofie M. E.
|
|
2013
|
|
3 |
p. 233-237
|
artikel
|
| 53 |
Fertility, Pregnancy and Childbirth in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
|
Amato, Maria Pia
|
|
2015
|
|
3 |
p. 207-220
|
artikel
|
| 54 |
First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat
|
Antonijoan, Rosa María
|
|
|
|
3 |
p. 331-344
|
artikel
|
| 55 |
GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam
|
Sankar, Raman
|
|
2012
|
|
3 |
p. 229-244
|
artikel
|
| 56 |
Gadolinium-Based Contrast Agent-Related Toxicities
|
Pasquini, Luca
|
|
2018
|
|
3 |
p. 229-240
|
artikel
|
| 57 |
Genetic Influences on Response to Mood Stabilizers in Bipolar Disorder
|
Rybakowski, Janusz K.
|
|
2013
|
|
3 |
p. 165-173
|
artikel
|
| 58 |
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
|
Lattanzi, Simona
|
|
|
|
3 |
p. 265-281
|
artikel
|
| 59 |
Immunoregulatory and/or Anti-inflammatory Agents for the Management of Core and Associated Symptoms in Individuals with Autism Spectrum Disorder: A Narrative Review of Randomized, Placebo-Controlled Trials
|
Arteaga-Henríquez, Gara
|
|
|
|
3 |
p. 215-229
|
artikel
|
| 60 |
Impact of Drug Manipulation on Seizure Freedom in Adults with Uncontrolled Epilepsy: A Prospective Controlled Study in Rural China
|
Hao, Xiaoting
|
|
2016
|
|
3 |
p. 237-243
|
artikel
|
| 61 |
Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis
|
Roy, Shumita
|
|
2016
|
|
3 |
p. 209-225
|
artikel
|
| 62 |
Infection Risk in Patients on Multiple Sclerosis Therapeutics
|
Williamson, Eric M.
|
|
2015
|
|
3 |
p. 229-244
|
artikel
|
| 63 |
Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment
|
Goldstein, Rachel
|
|
|
|
3 |
p. 203-214
|
artikel
|
| 64 |
Ketamine for Treatment-Resistant Unipolar Depression
|
Mathew, Sanjay J.
|
|
2012
|
|
3 |
p. 189-204
|
artikel
|
| 65 |
Kleptomania
|
Durst, Rimona
|
|
|
|
3 |
p. 185-195
|
artikel
|
| 66 |
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
|
Jann, Michael W.
|
|
2018
|
|
3 |
p. 241-257
|
artikel
|
| 67 |
Lurasidone: A Review of Its Use in Adult Patients with Bipolar I Depression
|
Sanford, Mark
|
|
2015
|
|
3 |
p. 253-263
|
artikel
|
| 68 |
Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates
|
Marcinkowska, Monika
|
|
|
|
3 |
p. 243-268
|
artikel
|
| 69 |
Managing an Unprovoked First Seizure in Adults
|
Gloss, David S.
|
|
2016
|
|
3 |
p. 179-183
|
artikel
|
| 70 |
Managing Cognitive Dysfunction through the Continuum of Alzheimer’s Disease
|
Delrieu, Julien
|
|
|
|
3 |
p. 213-226
|
artikel
|
| 71 |
Menstrual Migraine
|
Lay, Christine L.
|
|
|
|
3 |
p. 189-195
|
artikel
|
| 72 |
Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug
|
Richard, Muriel
|
|
|
|
3 |
p. 311-323
|
artikel
|
| 73 |
Neuroprotection for Ischaemic Stroke
|
Liebeskind, David S.
|
|
|
|
3 |
p. 165-174
|
artikel
|
| 74 |
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases
|
Batista, Andre F.
|
|
2018
|
|
3 |
p. 209-223
|
artikel
|
| 75 |
Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues
|
Grieb, Pawel
|
|
2014
|
|
3 |
p. 185-193
|
artikel
|
| 76 |
Neuropsychiatric Adverse Events Associated with Statins: Epidemiology, Pathophysiology, Prevention and Management
|
Tuccori, Marco
|
|
2014
|
|
3 |
p. 249-272
|
artikel
|
| 77 |
Newer Antiepileptic Drugs for Status Epilepticus in Adults: What’s the Evidence?
|
Beuchat, Isabelle
|
|
2018
|
|
3 |
p. 259-267
|
artikel
|
| 78 |
Nogo-A Antibodies for Progressive Multiple Sclerosis
|
Ineichen, Benjamin V.
|
|
2017
|
|
3 |
p. 187-198
|
artikel
|
| 79 |
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing
|
Swainson, Jennifer
|
|
|
|
3 |
p. 239-251
|
artikel
|
| 80 |
Novel Therapeutic Strategies for Traumatic Brain Injury: Acute Antioxidant Reinforcement
|
Fernández-Gajardo, Rodrigo
|
|
2014
|
|
3 |
p. 229-248
|
artikel
|
| 81 |
Open-Label Treatment with Desvenlafaxine in Postmenopausal Women with Major Depressive Disorder Not Responding to Acute Treatment with Desvenlafaxine or Escitalopram
|
Soares, Claudio N.
|
|
|
|
3 |
p. 227-238
|
artikel
|
| 82 |
Outcome Measures in Clinical Trials for Multiple Sclerosis
|
Munster, Caspar E. P. van
|
|
2017
|
|
3 |
p. 217-236
|
artikel
|
| 83 |
Pain Freedom at 2 Hours in Migraine after Telcagepant 300 mg
|
Tfelt-Hansen, Peer
|
|
|
|
3 |
p. 269-270
|
artikel
|
| 84 |
PEGylation of Interferon-β-1a
|
Kieseier, Bernd C.
|
|
2012
|
|
3 |
p. 205-214
|
artikel
|
| 85 |
Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis
|
Shkodina, Anastasiia D.
|
|
|
|
3 |
p. 205-224
|
artikel
|
| 86 |
Pharmacotherapy of Acute Mania: Monotherapy or Combination Therapy with Mood Stabilizers and Antipsychotics?
|
Grande, Iria
|
|
2015
|
|
3 |
p. 221-227
|
artikel
|
| 87 |
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development
|
Frieder, Ariela
|
|
2019
|
|
3 |
p. 265-282
|
artikel
|
| 88 |
Plant-Based Medicines for Anxiety Disorders, Part 1
|
Sarris, Jerome
|
|
2013
|
|
3 |
p. 207-219
|
artikel
|
| 89 |
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
|
Yu, Huixin
|
|
|
|
3 |
p. 283-300
|
artikel
|
| 90 |
Potential of Oxytocin in the Treatment of Schizophrenia
|
Shilling, Paul D.
|
|
2016
|
|
3 |
p. 193-208
|
artikel
|
| 91 |
Problems in the Descriptions of the Psychiatric Inclusion and Exclusion Criteria in Publications of Antidepressant Efficacy Trials: A Qualitative Review and Recommendations for Improved Clarity
|
Zimmerman, Mark
|
|
2016
|
|
3 |
p. 185-191
|
artikel
|
| 92 |
Prospects for the Pharmacological Prevention of Post-Traumatic Stress in Vulnerable Individuals
|
Ostrowski, Sarah A.
|
|
2014
|
|
3 |
p. 195-203
|
artikel
|
| 93 |
Psychotic and Mood Disorders Associated with the Perimenopausal Period
|
Robinson, Gail Erlick
|
|
|
|
3 |
p. 175-184
|
artikel
|
| 94 |
Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management
|
Jain, Neeranjali S.
|
|
|
|
3 |
p. 283-289
|
artikel
|
| 95 |
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
|
Costa-Frossard França, Lucienne
|
|
|
|
3 |
p. 231-238
|
artikel
|
| 96 |
Recent Advances in the Treatment of Huntington’s Disease: Targeting DNA and RNA
|
Shannon, Kathleen M.
|
|
|
|
3 |
p. 219-228
|
artikel
|
| 97 |
Recent Progress in Understanding the Pathophysiology of Post-Traumatic Stress Disorder
|
Bailey, Christopher R.
|
|
2013
|
|
3 |
p. 221-232
|
artikel
|
| 98 |
Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
|
Blair, Hannah A.
|
|
|
|
3 |
p. 255-265
|
artikel
|
| 99 |
Risk of Road Traffic Accidents in Patients Discharged Following Treatment for Psychotropic Drug Overdose
|
Dassanayake, Tharaka L.
|
|
2012
|
|
3 |
p. 269-276
|
artikel
|
| 100 |
Role of Cannabinoids in Multiple Sclerosis
|
Zajicek, John P.
|
|
|
|
3 |
p. 187-201
|
artikel
|
| 101 |
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects
|
Shen, Qi
|
|
|
|
3 |
p. 231-242
|
artikel
|
| 102 |
Serotonin–Norepinephrine Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor Use and Risk of Fractures: A New-User Cohort Study Among US Adults Aged 50 Years and Older
|
Lanteigne, Amy
|
|
2015
|
|
3 |
p. 245-252
|
artikel
|
| 103 |
Sleep Disorders in Patients with Traumatic Brain Injury
|
Castriotta, Richard J.
|
|
|
|
3 |
p. 175-185
|
artikel
|
| 104 |
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders
|
Harris, Sharonda S.
|
|
|
|
3 |
p. 253-264
|
artikel
|
| 105 |
The Pharmacology and Clinical Outcomes of Amphetamines to Treat ADHD
|
Hodgkins, Paul
|
|
2012
|
|
3 |
p. 245-268
|
artikel
|
| 106 |
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants
|
Costi, Sara
|
|
|
|
3 |
p. 207-216
|
artikel
|
| 107 |
Transdermal Therapy for Attention-Deficit Hyperactivity Disorder with the Methylphenidate Patch (MTS)
|
Findling, Robert L.
|
|
2014
|
|
3 |
p. 217-228
|
artikel
|
| 108 |
Treatment of Epileptic Encephalopathies
|
McTague, Amy
|
|
2013
|
|
3 |
p. 175-184
|
artikel
|
| 109 |
Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential
|
Serafini, Anna
|
|
2019
|
|
3 |
p. 195-208
|
artikel
|
| 110 |
Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis
|
Chen, Shih-Yu
|
|
2019
|
|
3 |
p. 225-238
|
artikel
|
| 111 |
Understanding the Impact of Stimulants on Sleep in ADHD: Evidence from Systematic Assessment of Sleep in Adults
|
Surman, Craig B. H.
|
|
|
|
3 |
p. 253-260
|
artikel
|
| 112 |
Unmet Needs in Psychodermatology: A Narrative Review
|
Christensen, Rachel E.
|
|
|
|
3 |
p. 193-204
|
artikel
|
| 113 |
Vaccines for Multiple Sclerosis
|
Correale, Jorge
|
|
|
|
3 |
p. 175-198
|
artikel
|
| 114 |
Visual Field Defects with Vigabatrin
|
Kälviäinen, Reetta
|
|
|
|
3 |
p. 217-230
|
artikel
|
Tijdschrift beschrijving